Comparative effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the treatment of rheumatoid arthritis

Objective: In agreement with EULAR recommendations, a DMARD in combination with a biotherapy is the reference treatment because of the superior long-term clinical and radiographic outcomes. Methotrexate (MTX) is the cornerstone of combination therapy but is in some cases contra-indicated or poorly t...

Descripción completa

Detalles Bibliográficos
Autores: Narváez García, Francisco Javier, Díaz-Torné, César, Magallares, Berta, Hernández Miguel, María Victoria, Reina, Delia, Corominas, Héctor, Sanmartí Sala, Raimon, Rodríguez de la Serna, Arturo, Llobet, Josep Maria, Nolla Solé, Joan Miquel
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2015
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/111111
Acceso en línea:https://hdl.handle.net/2445/111111
Access Level:acceso abierto
Palabra clave:Anticossos monoclonals
Artritis reumatoide
Metotrexat
Medicaments
Efectes secundaris dels medicaments
Interaccions dels medicaments
Monoclonal antibodies
Rheumatoid arthritis
Methotrexate
Drugs
Drug side effects
Drug interactions
id ES_56d9fff4a641d96bfcd034238edfdb6c
oai_identifier_str oai:recercat.cat:2445/111111
network_acronym_str ES
network_name_str España
repository_id_str
spelling Comparative effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the treatment of rheumatoid arthritisNarváez García, Francisco JavierDíaz-Torné, CésarMagallares, BertaHernández Miguel, María VictoriaReina, DeliaCorominas, HéctorSanmartí Sala, RaimonRodríguez de la Serna, ArturoLlobet, Josep MariaNolla Solé, Joan MiquelAnticossos monoclonalsArtritis reumatoideMetotrexatMedicamentsEfectes secundaris dels medicamentsInteraccions dels medicamentsMonoclonal antibodiesRheumatoid arthritisMethotrexateDrugsDrug side effectsDrug interactionsObjective: In agreement with EULAR recommendations, a DMARD in combination with a biotherapy is the reference treatment because of the superior long-term clinical and radiographic outcomes. Methotrexate (MTX) is the cornerstone of combination therapy but is in some cases contra-indicated or poorly tolerated. This observational study aimed to compare the effectiveness and safety of TCZ in combination with either MTX or leflunomide (LEF) in the treatment of patients with active rheumatoid arthritis (RA) and an inadequate response to one or more DMARDs and/or biological agents in a real-world setting. Methods: We performed an ambispective review of 91 patients with active RA who were routinely treated with TCZ plus MTX or LEF. A comparative study between the two combinations of treatment was performed at 6 months of follow-up considering 3 outcomes: improvement of RA disease activity, evolution of functional disability, and tolerability and side effect profile. Results: Of the 91 patients, 62 received TCZ with MTX and 29 received TCZ with LEF. Eighty-one patients were followed for 6 months, and the remaining 10 patients discontinued treatment due to serious adverse events. At baseline, there were no significant differences between the groups in terms of the main clinical and laboratory data or in the number of previous DMARDs and biological agents used. At 6 months, there were no significant differences between the combinations in terms of disease activity and functional disability. Serious adverse events occurred in 11% and 10% of the patients treated in combination with MTX and LEF, respectively. Conclusion: Our preliminary data support the argument that LEF is an effective and safe (equivalent) alternative to MTX for combination treatment with TCZ.Public Library of Science (PLoS)2017201720152017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion9 p.application/pdfhttps://hdl.handle.net/2445/111111Articles publicats en revistes (Ciències Clíniques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1371/journal.pone.0123392PLoS One, 2015, vol. 10, num. 4, p. e0123392https://doi.org/10.1371/journal.pone.0123392cc-by (c) Narváez García, Francisco Javier et al., 2015http://creativecommons.org/licenses/by/3.0/esinfo:eu-repo/semantics/openAccessoai:recercat.cat:2445/1111112026-05-29T05:05:01Z
dc.title.none.fl_str_mv Comparative effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the treatment of rheumatoid arthritis
title Comparative effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the treatment of rheumatoid arthritis
spellingShingle Comparative effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the treatment of rheumatoid arthritis
Narváez García, Francisco Javier
Anticossos monoclonals
Artritis reumatoide
Metotrexat
Medicaments
Efectes secundaris dels medicaments
Interaccions dels medicaments
Monoclonal antibodies
Rheumatoid arthritis
Methotrexate
Drugs
Drug side effects
Drug interactions
title_short Comparative effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the treatment of rheumatoid arthritis
title_full Comparative effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the treatment of rheumatoid arthritis
title_fullStr Comparative effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the treatment of rheumatoid arthritis
title_full_unstemmed Comparative effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the treatment of rheumatoid arthritis
title_sort Comparative effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the treatment of rheumatoid arthritis
dc.creator.none.fl_str_mv Narváez García, Francisco Javier
Díaz-Torné, César
Magallares, Berta
Hernández Miguel, María Victoria
Reina, Delia
Corominas, Héctor
Sanmartí Sala, Raimon
Rodríguez de la Serna, Arturo
Llobet, Josep Maria
Nolla Solé, Joan Miquel
author Narváez García, Francisco Javier
author_facet Narváez García, Francisco Javier
Díaz-Torné, César
Magallares, Berta
Hernández Miguel, María Victoria
Reina, Delia
Corominas, Héctor
Sanmartí Sala, Raimon
Rodríguez de la Serna, Arturo
Llobet, Josep Maria
Nolla Solé, Joan Miquel
author_role author
author2 Díaz-Torné, César
Magallares, Berta
Hernández Miguel, María Victoria
Reina, Delia
Corominas, Héctor
Sanmartí Sala, Raimon
Rodríguez de la Serna, Arturo
Llobet, Josep Maria
Nolla Solé, Joan Miquel
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Anticossos monoclonals
Artritis reumatoide
Metotrexat
Medicaments
Efectes secundaris dels medicaments
Interaccions dels medicaments
Monoclonal antibodies
Rheumatoid arthritis
Methotrexate
Drugs
Drug side effects
Drug interactions
topic Anticossos monoclonals
Artritis reumatoide
Metotrexat
Medicaments
Efectes secundaris dels medicaments
Interaccions dels medicaments
Monoclonal antibodies
Rheumatoid arthritis
Methotrexate
Drugs
Drug side effects
Drug interactions
description Objective: In agreement with EULAR recommendations, a DMARD in combination with a biotherapy is the reference treatment because of the superior long-term clinical and radiographic outcomes. Methotrexate (MTX) is the cornerstone of combination therapy but is in some cases contra-indicated or poorly tolerated. This observational study aimed to compare the effectiveness and safety of TCZ in combination with either MTX or leflunomide (LEF) in the treatment of patients with active rheumatoid arthritis (RA) and an inadequate response to one or more DMARDs and/or biological agents in a real-world setting. Methods: We performed an ambispective review of 91 patients with active RA who were routinely treated with TCZ plus MTX or LEF. A comparative study between the two combinations of treatment was performed at 6 months of follow-up considering 3 outcomes: improvement of RA disease activity, evolution of functional disability, and tolerability and side effect profile. Results: Of the 91 patients, 62 received TCZ with MTX and 29 received TCZ with LEF. Eighty-one patients were followed for 6 months, and the remaining 10 patients discontinued treatment due to serious adverse events. At baseline, there were no significant differences between the groups in terms of the main clinical and laboratory data or in the number of previous DMARDs and biological agents used. At 6 months, there were no significant differences between the combinations in terms of disease activity and functional disability. Serious adverse events occurred in 11% and 10% of the patients treated in combination with MTX and LEF, respectively. Conclusion: Our preliminary data support the argument that LEF is an effective and safe (equivalent) alternative to MTX for combination treatment with TCZ.
publishDate 2015
dc.date.none.fl_str_mv 2015
2017
2017
2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/111111
url https://hdl.handle.net/2445/111111
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0123392
PLoS One, 2015, vol. 10, num. 4, p. e0123392
https://doi.org/10.1371/journal.pone.0123392
dc.rights.none.fl_str_mv cc-by (c) Narváez García, Francisco Javier et al., 2015
http://creativecommons.org/licenses/by/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Narváez García, Francisco Javier et al., 2015
http://creativecommons.org/licenses/by/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9 p.
application/pdf
dc.publisher.none.fl_str_mv Public Library of Science (PLoS)
publisher.none.fl_str_mv Public Library of Science (PLoS)
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408409130893312
score 15.81155

Similares en LA Referencia